RU2500397C1 - Бронхолитическое средство на основе простагландина - Google Patents
Бронхолитическое средство на основе простагландина Download PDFInfo
- Publication number
- RU2500397C1 RU2500397C1 RU2012116226/15A RU2012116226A RU2500397C1 RU 2500397 C1 RU2500397 C1 RU 2500397C1 RU 2012116226/15 A RU2012116226/15 A RU 2012116226/15A RU 2012116226 A RU2012116226 A RU 2012116226A RU 2500397 C1 RU2500397 C1 RU 2500397C1
- Authority
- RU
- Russia
- Prior art keywords
- drug
- keto
- dihydroxy
- obstructive
- inhalation
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 19
- 229940079593 drug Drugs 0.000 title claims abstract description 13
- 229940124630 bronchodilator Drugs 0.000 title abstract description 13
- 230000001813 broncholytic effect Effects 0.000 title abstract 2
- 150000003180 prostaglandins Chemical class 0.000 title description 3
- 208000006673 asthma Diseases 0.000 claims abstract description 15
- 239000002253 acid Substances 0.000 claims abstract description 14
- 230000000414 obstructive effect Effects 0.000 claims abstract description 10
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 9
- 206010006451 bronchitis Diseases 0.000 claims abstract description 7
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims abstract description 5
- 238000011282 treatment Methods 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 210000002345 respiratory system Anatomy 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 229940041682 inhalant solution Drugs 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 208000023504 respiratory system disease Diseases 0.000 abstract description 3
- 230000003182 bronchodilatating effect Effects 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 230000004071 biological effect Effects 0.000 abstract 1
- 150000003166 prostaglandin E2 derivatives Chemical class 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 5
- 239000013543 active substance Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 description 4
- 231100001274 therapeutic index Toxicity 0.000 description 4
- 208000009079 Bronchial Spasm Diseases 0.000 description 3
- 208000014181 Bronchial disease Diseases 0.000 description 3
- 206010006482 Bronchospasm Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 description 3
- 239000000644 isotonic solution Substances 0.000 description 3
- SGMBTYBNUOWYOV-CXZSOYKBSA-N nitroproston Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(=O)OC(CO[N+]([O-])=O)CO[N+]([O-])=O SGMBTYBNUOWYOV-CXZSOYKBSA-N 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 2
- ASIGVDLTBLZXNC-UHFFFAOYSA-N 1,3-dinitroglycerol Chemical compound [O-][N+](=O)OCC(O)CO[N+]([O-])=O ASIGVDLTBLZXNC-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229940125388 beta agonist Drugs 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 239000000168 bronchodilator agent Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 208000011623 Obstructive Lung disease Diseases 0.000 description 1
- 102000008866 Prostaglandin E receptors Human genes 0.000 description 1
- 108010088540 Prostaglandin E receptors Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000024716 acute asthma Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000808 adrenergic beta-agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- WXAXNYYAYJKARR-UHFFFAOYSA-N benzene;2-(1,4-dioxan-2-yl)acetic acid Chemical compound C1=CC=CC=C1.OC(=O)CC1COCCO1 WXAXNYYAYJKARR-UHFFFAOYSA-N 0.000 description 1
- TXHIDIHEXDFONW-UHFFFAOYSA-N benzene;propan-2-one Chemical compound CC(C)=O.C1=CC=CC=C1 TXHIDIHEXDFONW-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 229940125369 inhaled corticosteroids Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229960000665 norflurane Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000017953 prostanoid receptors Human genes 0.000 description 1
- 108050007059 prostanoid receptors Proteins 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2012116226/15A RU2500397C1 (ru) | 2012-04-24 | 2012-04-24 | Бронхолитическое средство на основе простагландина |
| AU2013253042A AU2013253042B2 (en) | 2012-04-24 | 2013-03-01 | Broncholytic drug on the basis of prostaglandin |
| JP2015508895A JP6126204B2 (ja) | 2012-04-24 | 2013-03-01 | プロスタグランジンを主成分とした気管支拡張剤 |
| CN201380022111.6A CN104470510A (zh) | 2012-04-24 | 2013-03-01 | 一种基于前列腺素的支气管松解药 |
| EA201401178A EA027724B1 (ru) | 2012-04-24 | 2013-03-01 | Бронхолитическое средство на основе простагландина |
| PCT/RU2013/000163 WO2013162416A1 (ru) | 2012-04-24 | 2013-03-01 | Бронхолитическое средство на основе простагландина |
| BR112014026610A BR112014026610A2 (pt) | 2012-04-24 | 2013-03-01 | medicamento e método para tratar doenças inflamatórias ou obstrutivas do trato respiratório e usos do éster 1’,3’-dinitroglicerol do ácido 11(s),15(s)-dihi-droxi-9-ceto-5z,13e-prostadienoico |
| EP13781656.7A EP2842554B1 (en) | 2012-04-24 | 2013-03-01 | Broncholytic drug on the basis of prostaglandin |
| CA2871601A CA2871601C (en) | 2012-04-24 | 2013-03-01 | Broncholytic drug on the basis of prostaglandin |
| US14/397,092 US9408820B2 (en) | 2012-04-24 | 2013-03-01 | Broncholytic drug on the basis of prostaglandin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2012116226/15A RU2500397C1 (ru) | 2012-04-24 | 2012-04-24 | Бронхолитическое средство на основе простагландина |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2012116226A RU2012116226A (ru) | 2013-10-27 |
| RU2500397C1 true RU2500397C1 (ru) | 2013-12-10 |
Family
ID=49446371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012116226/15A RU2500397C1 (ru) | 2012-04-24 | 2012-04-24 | Бронхолитическое средство на основе простагландина |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9408820B2 (enExample) |
| EP (1) | EP2842554B1 (enExample) |
| JP (1) | JP6126204B2 (enExample) |
| CN (1) | CN104470510A (enExample) |
| AU (1) | AU2013253042B2 (enExample) |
| BR (1) | BR112014026610A2 (enExample) |
| CA (1) | CA2871601C (enExample) |
| EA (1) | EA027724B1 (enExample) |
| RU (1) | RU2500397C1 (enExample) |
| WO (1) | WO2013162416A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170326094A1 (en) * | 2014-12-09 | 2017-11-16 | Nestec S.A. | Uses of bioactive lipids |
| RU2662099C1 (ru) * | 2017-10-16 | 2018-07-23 | Общество с ограниченной ответственностью "Гурус БиоФарм" | Фармацевтические композиции для ингаляций, содержащие нитропростон |
| RU2695068C1 (ru) * | 2018-06-26 | 2019-07-19 | Общество с ограниченной ответственностью "Гурус БиоФарм" | Средство для лечения хронических облитерирующих заболеваний периферических сосудов на основе простагландина |
| CN117924133A (zh) * | 2022-10-17 | 2024-04-26 | 广州楷石医药有限公司 | 一种前列地尔偶联一氧化氮供体药物及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2067094C1 (ru) * | 1993-09-27 | 1996-09-27 | Владимир Виленович Безуглов | 1,3-динитроглицериновые эфиры полиненасыщенных жирных кислот, гидроксипроизводных полиненасыщенных жирных кислот и простагландинов и способы их получения |
| US5625083A (en) * | 1995-06-02 | 1997-04-29 | Bezuglov; Vladimir V. | Dinitroglycerol esters of unsaturated fatty acids and prostaglandins |
-
2012
- 2012-04-24 RU RU2012116226/15A patent/RU2500397C1/ru active
-
2013
- 2013-03-01 EP EP13781656.7A patent/EP2842554B1/en not_active Not-in-force
- 2013-03-01 WO PCT/RU2013/000163 patent/WO2013162416A1/ru not_active Ceased
- 2013-03-01 JP JP2015508895A patent/JP6126204B2/ja not_active Expired - Fee Related
- 2013-03-01 BR BR112014026610A patent/BR112014026610A2/pt not_active Application Discontinuation
- 2013-03-01 EA EA201401178A patent/EA027724B1/ru not_active IP Right Cessation
- 2013-03-01 CA CA2871601A patent/CA2871601C/en active Active
- 2013-03-01 AU AU2013253042A patent/AU2013253042B2/en not_active Ceased
- 2013-03-01 CN CN201380022111.6A patent/CN104470510A/zh active Pending
- 2013-03-01 US US14/397,092 patent/US9408820B2/en active Active
Non-Patent Citations (1)
| Title |
|---|
| Серков И.В. и др. Многофункциональные соединения, содержащие органические нитраты-прототипы гибридных лекарственных препаратов. - Успехи химии, 2009, №78 (5), с.442-465. Чучалин А.Г. Бронхиальная астма. - М.: Медицина, 1985, 160 с. GAUVREAU G.M. et al. «Protective effects of inhaled PGE 2 on allergen-induced airway responses and airway inflammation», American Journal of Respiratory and Critical Care Medicine, Volume 159, Issue 1, 1999, Pages 31-36. * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6126204B2 (ja) | 2017-05-10 |
| EP2842554A1 (en) | 2015-03-04 |
| CA2871601A1 (en) | 2013-10-31 |
| US9408820B2 (en) | 2016-08-09 |
| BR112014026610A2 (pt) | 2017-07-18 |
| EA201401178A1 (ru) | 2015-10-30 |
| AU2013253042A1 (en) | 2014-12-11 |
| EP2842554B1 (en) | 2018-10-24 |
| CA2871601C (en) | 2020-02-18 |
| EP2842554A4 (en) | 2016-01-06 |
| EA027724B1 (ru) | 2017-08-31 |
| US20150141505A1 (en) | 2015-05-21 |
| JP2016506359A (ja) | 2016-03-03 |
| CN104470510A (zh) | 2015-03-25 |
| AU2013253042B2 (en) | 2017-08-31 |
| WO2013162416A1 (ru) | 2013-10-31 |
| RU2012116226A (ru) | 2013-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG98011A (bg) | Нови стероидни естери | |
| US8765994B2 (en) | Ship 1 modulators | |
| JP2000509716A (ja) | アンドロステン誘導体 | |
| RU2500397C1 (ru) | Бронхолитическое средство на основе простагландина | |
| JP3114895B2 (ja) | 炎症性疾患の処置のための薬剤調製物 | |
| Zhu et al. | Discovery of a novel series of α-terpineol derivatives as promising anti-asthmatic agents: Their design, synthesis, and biological evaluation | |
| EP1554304B1 (en) | Ship 1 modulators | |
| CN102648908B (zh) | 3-甲基-1-苯基-2-吡唑啉-5-酮与龙脑组合物的应用 | |
| US5481043A (en) | Phenone compounds, manufacturing method and pharmaceutical preparations containing them | |
| JP2016506359A5 (enExample) | ||
| US11447522B2 (en) | Potent soft anti-inflammatory corticosteroid compounds and uses thereof | |
| Zhou et al. | A novel strategy for development of glucocorticoids through non-genomic mechanism | |
| EP2987492B1 (en) | Use of 7-a-[9-(4,4,5,5,5 - pentafluoro-pentyl-sulfinyl)nonyl]-estra-1,3,5(10)-triene-3,17b-diol and derivatives thereof | |
| JPS6360949A (ja) | トリテルペン化合物及び制癌剤 | |
| US20240316073A1 (en) | Cannabidiolic acid esters for treating prader-willi syndrome | |
| CN101397330B (zh) | 具有抗炎活性的一种新型含氮药物 | |
| CN105380953B (zh) | 酸浆苦素p在制备治疗慢性阻塞性肺疾病的药物中的应用 | |
| CN106380400B (zh) | 一种萜品烯醇类化合物及其制备方法和应用 | |
| CN102250185B (zh) | 一种21位为nmda酯的糖皮质激素 | |
| CN117562915A (zh) | 一种腺苷衍生物在制备预防、缓解或治疗纤维化疾病的药物中的应用 | |
| CN107868088A (zh) | 苯并二氮杂*类氮氧化物 | |
| CN103159717A (zh) | 17-氢-9-去氢穿心莲内酯-3,19-二硫酸酯化物、制备方法及其制备药物用途 | |
| Simonelli et al. | A RESVERATROL–HYDROGEN SULFIDE DONOR HYBRID AS A MULTI-TARGET THERAPEUTIC STRATEGY FOR ALLERGIC ASTHMA | |
| CN106692976A (zh) | P‑糖蛋白抑制剂Gelucire44/14作为经口服的盐酸小檗碱吸收促进剂的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20151022 |
|
| HE4A | Notice of change of address of a patent owner |
Effective date: 20190813 |